Income Taxes (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended		6 Months Ended			3 Months Ended		6 Months Ended		3 Months Ended	6 Months Ended
	Mar. 28, 2014	Mar. 29, 2013	Mar. 28, 2014	Mar. 29, 2013	Sep. 27, 2013	Mar. 28, 2014 Separation Costs	Mar. 29, 2013 Separation Costs	Mar. 28, 2014 Separation Costs	Mar. 29, 2013 Separation Costs	Mar. 28, 2014 Cadence Pharmaceuticals, Inc.	Mar. 28, 2014 Cadence Pharmaceuticals, Inc.	Mar. 19, 2014 Cadence Pharmaceuticals, Inc.	Mar. 19, 2014 Completed Technology Ofirmev Cadence Pharmaceuticals, Inc.
Income Taxes [Line Items]
Provision for income taxes	$ (20.3)	$ 19.0	$ (3.7)	$ 36.1
(Loss) income from continuing operations before income taxes	(8.6)	53.5	54.4	90.4
Tax benefit on special items						0.4	1.0	1.1	1.3	20.7	20.7
Separation costs	2.6	14.4	4.8	26.4
Deferred tax liability, net increase due to acquisition												296.6
Deferred tax liabilities, acquired intangible asset													499.6
Deferred tax assets, acquired NOLs												196.2
Deferred tax asset, acquired federal and state tax credits												5.8
Deferred tax assets, acquired valuation allowance												7.3
Unrecognized tax benefits	105.0		105.0		100.1
Unrecognized tax benefits, net increase			4.9
Unrecognized tax benefits, additions related to prior period tax positions			11.5
Unrecognized tax benefits, additions related to current year tax positions			1.4
Unrecognized tax benefits, decrease related to settlements			0.2
Unrecognized tax benefits, lapse of statute of limitations			7.8
Unrecognized tax benefits, which if favorably settled would benefit the effective tax rate	101.2		101.2
Interest accrued on unrecognized tax benefits	56.1		56.1		62.1
Unrecognized tax benefits that would impact effective tax rate, upper bound of change	44.9		44.9
Income tax penalties and interest accrued that would impact effective tax rate, upper bound of change	$ 26.4		$ 26.4